Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 108; no. 4; pp. 1163 - 1167
Main Authors Jallouk, Andrew P, Gouni, Sushanth, Westin, Jason, Feng, Lei, Mistry, Haleigh, Steiner, Raphael E, James, Jinsu, Noorani, Mansoor, Horowitz, Sandra, Puebla-Osorio, Nahum, Fayad, Luis E, Iyer, Swaminathan P, Hawkins, Misha, Flowers, Christopher R, Ahmed, Sairah, Nastoupil, Loretta J, Kebriaei, Partow, Shpall, Elizabeth J, Neelapu, Sattva S, Nieto, Yago, Strati, Paolo
Format Journal Article
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.04.2023
Ferrata Storti Foundation
Subjects
Antigens, CD19
Biological Products - therapeutic use
Humans
Immunotherapy, Adoptive
Letter to the Editor
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - pathology
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-1
content type line 63
ObjectType-Correspondence-2
PS is a consultant for Kite-Gilead, Roche-Genentech, Hutchinson MediPharma, ADC Therapeutics, Incyte Morphosis and TG Therapeutics; and received research funds from Sobi Pharmaceuticals, Astrazeneca-Acerta, ALX Oncology and ADC Therapeutics. RES has received research funding from Seagen, BMS, Rafael Pharmaceuticals and GSK. SA received research funding from Seattle Genetics, Merck, Xencor, and Tessa Therapeutics and has membership on Tessa Therapeutic’s advisory committee. JN reports honoraria from Celgene, Genentech, Gilead, Janssen, Juno, Novartis, Spectrum, TG Therapeutics and research support from Celgene, Genentech, Janssen, Karus Therapeutics, and Merck. SSN served as consultant to Kite, a Gilead Company, Merck, Bristol-Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Cell Medica/Kuur, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr, and Unum Therapeutics; received research support from Kite, a Gilead Company, Bristol-Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene Therapeutics, Precision Biosciences, and Acerta; received royalties from Takeda Pharmaceuticals, and has intellectual property related to cell therapy.
Disclosures
Contributions
APJ and SG analyzed data, and wrote the paper; JW, RES, LEF, SPI, CRF, SA, LJN, PK, EJS and SSN provided clinical care to patients and co-authored the paper; HM, JJ, MN and SH collected clinical data and co-authored the paper; APJ, NPO and SSN performed correlative studies and co-authored the paper; LF provided statistical support and co-authored the paper; PS and YN designed the study, analyzed the data, provided clinical care to patients, and wrote the paper.
Data-sharing statement
De-identified data are available upon request from the corresponding author.
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2022.281954